Actinium Pharmaceuticals, Inc.ATNMNYSE
Loading
Year-over-year research & development expense growth
Percentile
P31
Within normal range
vs 5Y Ago
-1.7x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q3 2025 | -13.54% |
| Q2 2025 | -37.63% |
| Q1 2025 | 62.69% |
| Q4 2024 | -51.87% |
| Q3 2024 | 10.84% |
| Q2 2024 | 34.54% |
| Q1 2024 | -18.94% |
| Q4 2023 | -30.67% |
| Q3 2023 | 5.06% |
| Q2 2023 | 38.51% |
| Q1 2023 | 9.44% |
| Q4 2022 | 9.50% |
| Q3 2022 | 46.14% |
| Q2 2022 | 5.91% |
| Q1 2022 | -19.83% |
| Q4 2021 | 12.13% |
| Q3 2021 | 29.66% |
| Q2 2021 | -15.08% |
| Q1 2021 | -7.82% |
| Q4 2020 | 22.47% |
| Q3 2020 | 7.98% |
| Q2 2020 | -15.49% |
| Q1 2020 | 23.04% |
| Q4 2019 | -30.15% |
| Q3 2019 | 20.45% |
| Q2 2019 | -7.52% |
| Q1 2019 | -14.73% |
| Q4 2018 | 20.47% |
| Q3 2018 | 26.95% |
| Q2 2018 | -25.50% |
| Q1 2018 | 21.54% |
| Q4 2017 | -25.92% |
| Q3 2017 | 13.20% |
| Q2 2017 | -2.78% |
| Q1 2017 | 15.43% |
| Q4 2016 | -31.38% |
| Q3 2016 | 37.08% |
| Q2 2016 | 10.17% |
| Q1 2016 | 44.97% |
| Q4 2015 | -8.17% |